An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 15th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2026, is one of 17 observational ones, and was the 47th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Germany, Japan and 1 more country
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
Bayer · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 98 across the 32 interventional studies, 4,613 across the 17 observational. Of the 39 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
4 of the studies in Renal Insufficiency, Chronic by Bayer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT06763146BayerAn Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | 2026-11-30 |
| NCT06278207BayerAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | 2027-09-30 |
| NCT07232537BayerAn Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
Chronic kidney disease (CKD) is common in people with type 2 diabetes. It can get worse over time and may lead to kidney failure and heart problems. Doctors often track kidney health using blood and urine tests, including the estimated glomerular filtration rate (eGFR) and the urine albumin-to-creatinine ratio (UACR). There are also tools that combine routine laboratory test results to estimate a person's risk of their kidney disease getting worse. One of these tools is called the Klinrisk model.
The study drug, finerenone, is already approved for doctors to prescribe to patients with CKD associated with T2D and albumin in the urine.
Finerenone works by blocking the mineralocorticoid receptor, a protein involved in inflammation and scarring in the kidneys and heart. The study drug, finerenone, is a non-steroidal mineralocorticoid receptor modulator that aims to reduce harmful kidney and heart changes.
The main purpose of this study is to determine whether the Klinrisk score improves after 2 years of treatment with finerenone in adults with CKD associated with T2D who are treated in routine care. To achieve this, researchers will collect data on:
The study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.
Data will be collected from April 2026 to April 2029 and will cover a period of up to 24 months per participant. Data collection will occur over 5 visits that coincide with routine clinical care: inclusion, follow-up visits at 6, 12, and 18 months (±1 month), and a final visit at 24 months (±1 month).
Participants with a diagnosed of CKD and T2D will be enrolled after the decision for treatment with finerenone has been made by the treating physician.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are newly prescribed finerenone under routine treatment conditions.
Drug: Finerenone (Kerendia, BAY94-8862)
Decision will be taken by the treating physician to initiate treatment with finerenone.
Percentage of patients who show an improvement in the Klinrisk model score after 24 months of treatment with finerenone.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Percentage of patients who show an improvement in the Klinrisk model score after 12 months of treatment with finerenone.
Time frame: Up to 12 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of the composite outcome of kidney failure, a sustained decrease of at least 40% in the eGFR from the beginning of treatment with finerenone (index date), or death from renal causes.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Time to the composite endpoint of renal outcomes.
Composite outcome of kidney failure, a sustained decrease of at least 40% in the eGFR from the beginning of treatment with finerenone (index date), or death from renal causes.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) for kidney failure.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) for sustained decrease in eGFR to <15 mL/min/1.73 m2 maintained for at least 4 weeks.
eGFR = estimated glomerular filtration rate.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) for sustained ≥40% eGFR decline from baseline maintained for at least 4 weeks.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of KRT.
KRT = kidney replacement therapy.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of death from renal causes.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Change in UACR at months 6, 12, 18 and 24 (> 30%, 40% or >50%)
UACR = urinary albumin-to-creatinine ratio
Time frame: At months 6, 12, 18 and 24.
Change in eGFR chronic slope at months 6, 12, 18 and 24.
Time frame: At months 6, 12, 18 and 24.
Levels of NT-proBNP values.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of the composite outcome of death from CV causes, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of death from CV causes.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of nonfatal myocardial infarction.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of nonfatal stroke.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Cumulative incidence (%) of hospitalizations for heart failure.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Incidence rate of death from CV causes.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Incidence rate of nonfatal myocardial infarction.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Incidence rate of nonfatal stroke.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Incidence rate of hospitalization for heart failure.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Number of adverse events (AEs) that occur during the study period.
Time frame: Up to 30 days after the final treatment with finerenone.
Number of discontinuations of finerenone for AEs.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Number of hospitalizations for AEs.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Percentage of patients with hypokalemia, normokalemia and hyperkalemia.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Percentage of patients who maintain normokalemia over the entire follow-up.
This endpoint will be analysed in patients with normokalemia at the start of finerenone.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Incidence of acute kidney injury (AKI) requiring hospitalization.
Time frame: Up to 24 months from the beginning of treatment with finerenone.
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 36 months is above that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2029 → May 2029 and completion Apr 2029 → May 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →